See the DrugPatentWatch profile for Androgel
AndroGel is manufactured by AbbVie and Besins Healthcare [1].
What is AndroGel used for?
AndroGel is a prescription medication used for testosterone replacement therapy in adult males who have low or no testosterone [2]. This condition is also known as hypogonadism [3].
What are the different forms of AndroGel?
AndroGel is available as a topical gel that is applied to the skin. It comes in two strengths: 1% and 1.62% [2].
Who manufactures testosterone replacement therapies besides AbbVie and Besins?
Several companies manufacture testosterone replacement therapies. These include products that are delivered via injection, transdermal patch, gel, or implant. Some common manufacturers and their associated brands include Endo Pharmaceuticals (Testim), Upsher-Smith Laboratories (AdDeferred), and Eli Lilly and Company (Axiron) [4].
When does the patent for AndroGel expire?
Patent expiration dates for medications can be complex and may involve multiple patents covering different aspects of the drug. Information on specific patent expirations for AndroGel can be found on resources like DrugPatentWatch.com [5].
What are the risks associated with testosterone replacement therapy?
Testosterone replacement therapy, including AndroGel, carries potential risks. These can include an increased risk of heart attack, stroke, and blood clots. Other side effects may involve an enlarged prostate, acne, and changes in hair growth patterns. It's important for patients to discuss these risks with their healthcare provider [2].